Initiation of blood coagulation in different stages of normal pregnancy
Author Affiliations1Altai Affiliation of Hematology Research Center of Minzdrav of Russia 656045, Barnaul, Lyapidevskogo str., 1
2Altai Affiliation of Hematology Research Center of Minzdrav of Russia 656045, Barnaul, Lyapidevskogo str., 1
3Altai State Medical University of Minzdrav of Russia 656038, Barnaul, Lenina av., 40
4Altai Affiliation of Hematology Research Center of Minzdrav of Russia 656045, Barnaul, Lyapidevskogo str., 1
5Altai State Medical University of Minzdrav of Russia 656038, Barnaul, Lenina av., 40
6"Invitro-Sibir" LTD 630000, Novosibirsk, Krasnyi av., 218/2
Abstract
The purpose of the study was to analyse triggering mechanisms of blood coagulation activation in different stages of normal pregnancy and assessment of the possible role of their disorders for reproductive loss and preterm delivery. Materials and methods. 301 women were examined: non-pregnant women, women in different periods of normal pregnancy and on the 2-3rd day after spontaneous labor. Activity of tissue factor (TF), tissue factor pathway inhibitor (TFPI), the level of activated factor VIIa (FVIIa), fibrinopeptide A (FPA) and D-dimers were determined in venous blood plasma. Results and Discussion. Progressive increase in the activity of TF, the dynamics and intervals of TF and TFPI valid values, as well as the ratio of their activity at different stages in normal pregnancy (r = 0.15; p < 0.03) were defined. TF activity prevailed over TFPI activity ranging from 12-13 weeks, which was more significant in the later stages of gestation (34-36 weeks). TF activity value was directly related to the level of FVIIa (r = 0.21; p < 0.002), FPA (r = 0.23; p < 0.001) and D-dimers (r = 0.40; p < 0.001), indicating the successful implementation of coagulation potential in the blood of pregnant women which is not accompanied, however, by the development of clinically significant vascular ischemia. It is assumed that the high level of TF contributes not only to the activation of hemostasis, but also initiates termination of pregnancy and the onset of labor. Materials of the article define triggering mechanisms of increasing thrombogenicity of blood during pregnancy, and the data can be used as indicative values for the formation of groups at risk for thrombotic and obstetric complications.
Key words
References1. Bitsadze V.O., Makatsariya A.D., Khizroeva D.K. et al. Thrombophilia as a key link of the pathogenesis of pregnancy complications // Practicheskaya meditsina 2012. (5). 22-29. (in Russian)
2. Byshevskiy A.S., Polyakova V.A., Rudzevich A.Y. Hemostasis in normal pregnancy, pregnancy with arterial hypertension and preeclampsia // Tromboz, gemostaz i reologiya. 2010. 4. (44). 13-30. (in Russian)
3. Gil'manov A.Z. D-dimer: What? How? Who? For what purpose? // Klinicheskiy laboratorniy konsilium. 2009. 6. (31). 38-46. (in Russian)
4. Momot A.P., Kiryushchenkov P.A., Trukhina D.A. et al. Reference values of the level and activity of von Willebrand factor, metalloproteinase ADAMTS-13, activity of platelets in normal pregnancy.// Akusherstvo i ginekologiya. 2014. (2). 46-52. (in Russian)
5. Momot A.P., Tsyvkina L.P., Taranenko I.A. et al. Modern methods of recognition of thrombotic state of readiness: Monograph / Ed. A.P. Momot. Barnaul: publisher ASU, 2011. 138 p. (in Russian)
6. Shoykhet Y.N., Momot A.P., Elykomov V.A. The validation of new technology of non-heparin strengthen of anticoagulant properties of fresh frozen plasma with the substitutive homo component therapy of disseminated intravascular coagulation // Problemy klinicheskoy meditsiny. 2008. (5-6). 130-144. (in Russian)
7. Abbassi-Ghanavati M., Greer L.G., Cunningham F.G. Pregnancy and laboratory studies: a reference table for clinicians // Obstet. Gynecol. 2009. 114. 1326-1331.
8. Abdel Gader A.M., Al-Mishari A.A., Awadalla S.A. et al. Total and free tissue factor pathway inhibitor in pregnancy hypertension // Int. J. Gynaecol. Obstet. 2006. 95. 248-253.
9. Amiral J., Walenga, J.M., Fareed J. Development and performarnance characteristics of a competitive enzyme immunoassay for fibrinopeptide A // Semin. Thromb. Hemost. 1984. 10. 228-242.
10. Broze G.J. Jr, Girard T.J., Novotny W.F. Regulation of coagulation by a multivalent Kunitz-type inhibitor // Biochemistry. 1990. 29. 7539-7546.
11. Carson S.D., Ramsey C.A. Tissue factor (coagulation factor III) is present in placental microvilli and cofractionates with microvilli membrane proteins // Placenta. 1985. 6. (1). 5-12.
12. Edgington T.S., Mackman N., Brand K. et al. The structural biology of expression and function of tissue factor // Thromb. Haemost. 1991. 66. (1). 67-79.
13. Eichinger S. D-Dimer testing in pregnancy // Pathophysiol. Haemost. Thromb. 2003/2004. 33. 327-329.
14. Erez O., Hoppensteadt D., Than N.G. Tissue factor and its natural inhibitor in preeclampsia and SGA // J. Matern. Fetal. Neonatal. Med. 2008. 21. 855-859.
15. Erez O., Romero R., Vaisbuch E. et al. High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor // J. Matern. Fetal. Neonatal. Med. 2010. 23. (1). 23-33.
16. Hale S.A., Schonberg A., Badger G.J. et al. Relationship between prepregnancy and early pregnancy uterine blood flow and resistance index // Reprod. Sci. 2009. 16. (11). 1091-1096.
17. Heit J. Thrombophilia: clinical and laboratory assessment and management // Consultative Hemostasis and Thrombosis / Eds. C.S. Kithens, C.M. Kessler, B.A. Konkle. 3rd ed. Philadelphia: Saunders Elsevier, 2013. 205-239.
18. Hoffman M. Remodeling the blood coagulation cascade // J. Thromb. Thrombolysis. 2003. 16. (1-2). 17-20.
19. Hoke M., Kyrle P.A., Minar E. et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism // Thromb. Haemost. 2005. 94. 787-790.
20. Holmes V.A., Wallace J.M. Haemostasis in normal pregnancy: a balancing act? // Biochem. Soc. Trans. 2005. 33. (2). 428-432.
21. Hube F., Reverdiau P., Iochmann S. et al. Demonstration of a tissue factor pathway inhibitor 2 messenger RNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas // Biol. Reprod. 2003. 68. 1888-1894.
22. Kelley C.M., Bernstein I.M., Brummel-Ziedins K. Tissue factor dependent thrombin generation across pregnancy // Am. J. Obstet. Gynecol. 2012. 207. (2). 135e1-135e6.
23. Kline J., Williams G., Hernandez-Nino J. D-Dimer concentrations in normal pregnancy: New diagnostic thresholds are needed // Clin. Chem. 2005. 51. (5). 825-829.
24. Levi M. The coagulant response in sepsis and inflammation // Hamostaseologie. 2010. 30. (1). 10-12, 14-16.
25. Lockwood C.J., Krikun G., Caze R. et al. Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis // Ann. N. Y. Acad. Sci. 2008. 1127. 67-72.
26. Monagle P., Barnes C., Ignjatovic V. et al. Developmental haemostasis. Impact for clinical haemostasis laboratories // Thromb. Haemost. 2006. 95. (2). 362-372.
27. Sarig G., Blumenfeld Z., Leiba R. et al. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss // Thromb. Haemost. 2005. 94. 980-985.
28. Smith S.A. The cell-based model of coagulation // J. Vet. Emerg. Crit. Care. 2009. 19. (1). 3-10.
29. Uszynski M., Zekanowska E., Uszynski W. et al. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic fluid and blood plasma: implications for the mechanism of amniotic fluid embolism // Eur. J. Obstet. Gynecol. Reprod. Biol. 2001. 95. 163-166.
30. Walfish M., Neuman A., Wlody D. Maternal haemorrhage // Br. J. Anaesth. 2009. 103. (1). i47-i56.
About Authors (Correspondence):
Momot A.P. - doctor of medical sciences, professor, director, e-mail: xyzan@yandex.ru
Taranenko I.A. - candidate of medical sciences, researcher, e-mail: tarania@mail.ru
Belozerov D.Ye. - junior researcher, e-mail: dmitrbelozerov@yandex.ru
Tsyvkina L.P. - doctor of medical sciences, professor, senior research, e-mail: katerina-cyvkina@mail.ru
Fadeeva N.I. - doctor of medical sciences, professor, head of the department of obstetrics and gynecology № 1, e-mail: nat2fad@hotmail.com
Меdvedeva М.В. - doctor-laboratorian, e-mail: MMedvedeva@sib.invitro.ru
Full Text
